Levi & Korsinsky Alerts Investors in Altimmune, Inc. for Class Action Lawsuit Participation
Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, is urging investors in Altimmune, Inc. (NASDAQ: ALT) to come forward and participate in a class action lawsuit. This action is particularly relevant for those who suffered financial losses due to alleged securities fraud that occurred between August 10, 2023, and June 25, 2025. The firm aims to recover these losses on behalf of affected investors, who may not be aware of their eligibility for compensation.
According to the details of the case, Altimmune faced significant challenges following the release of top-line results from the IMPACT Phase 2b MASH trial of Pemvidutide on June 26, 2025. The results were disappointing, as they did not demonstrate the expected statistical significance in fibrosis reduction, a crucial endpoint for the trial. This underperformance was particularly alarming considering that the company had set inflated expectations prior to the release of the trial results. Investors were led to believe in a positive outcome, only to face a stark reality when the results were published.
The day after the announcement, Altimmune's share price plummeted from $7.71 to $3.61—an astonishing 53.2% drop in just one day. This drastic decrease resulted in substantial financial losses for many investors, thus creating a compelling basis for a class action suit.
Investors who experienced losses in Altimmune stock during the stipulated period are encouraged to act quickly, as the deadline to request appointment as lead plaintiff is October 6, 2025. It is important to note that participating investors are not obliged to take on this role to qualify for any potential recovery from the class action lawsuit. Levi & Korsinsky emphasizes that there are no associated costs or obligations for class members, making this a risk-free opportunity for affected investors to seek restitution.
Investors can obtain more information about joining the lawsuit by visiting the Levi & Korsinsky website or by contacting Joseph E. Levi, Esq. directly via email or phone. The firm has a strong track record, having secured millions of dollars for investors in similar cases over the past two decades, which highlights their capability to navigate complex securities litigation successfully.
Levi & Korsinsky has built a solid reputation in securities litigation, often being listed among the top firms for this type of legal action. With a dedicated team of over 70 professionals, the firm is well-equipped to handle the unique challenges posed by securities fraud cases. For seven consecutive years, they have ranked in ISS Securities Class Action Services' Top 50 Report, showcasing their success and reliability in championing the rights of investors.
For Altimmune investors looking to reclaim their losses following the recent securities fraud allegations, engaging with Levi & Korsinsky offers a valuable pathway toward potential recovery. With the looming deadline for participation in the class action, it is essential for affected investors to take prompt action. Interested parties should reach out to the firm as soon as possible to determine their eligibility and begin the process of seeking justice and compensation.
For more information, or to submit details of your case, please refer to the contact information provided, and take the first step towards asserting your rights as an investor.
Background of the Case
According to the details of the case, Altimmune faced significant challenges following the release of top-line results from the IMPACT Phase 2b MASH trial of Pemvidutide on June 26, 2025. The results were disappointing, as they did not demonstrate the expected statistical significance in fibrosis reduction, a crucial endpoint for the trial. This underperformance was particularly alarming considering that the company had set inflated expectations prior to the release of the trial results. Investors were led to believe in a positive outcome, only to face a stark reality when the results were published.
The day after the announcement, Altimmune's share price plummeted from $7.71 to $3.61—an astonishing 53.2% drop in just one day. This drastic decrease resulted in substantial financial losses for many investors, thus creating a compelling basis for a class action suit.
Class Action Details
Investors who experienced losses in Altimmune stock during the stipulated period are encouraged to act quickly, as the deadline to request appointment as lead plaintiff is October 6, 2025. It is important to note that participating investors are not obliged to take on this role to qualify for any potential recovery from the class action lawsuit. Levi & Korsinsky emphasizes that there are no associated costs or obligations for class members, making this a risk-free opportunity for affected investors to seek restitution.
Investors can obtain more information about joining the lawsuit by visiting the Levi & Korsinsky website or by contacting Joseph E. Levi, Esq. directly via email or phone. The firm has a strong track record, having secured millions of dollars for investors in similar cases over the past two decades, which highlights their capability to navigate complex securities litigation successfully.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has built a solid reputation in securities litigation, often being listed among the top firms for this type of legal action. With a dedicated team of over 70 professionals, the firm is well-equipped to handle the unique challenges posed by securities fraud cases. For seven consecutive years, they have ranked in ISS Securities Class Action Services' Top 50 Report, showcasing their success and reliability in championing the rights of investors.
Conclusion
For Altimmune investors looking to reclaim their losses following the recent securities fraud allegations, engaging with Levi & Korsinsky offers a valuable pathway toward potential recovery. With the looming deadline for participation in the class action, it is essential for affected investors to take prompt action. Interested parties should reach out to the firm as soon as possible to determine their eligibility and begin the process of seeking justice and compensation.
For more information, or to submit details of your case, please refer to the contact information provided, and take the first step towards asserting your rights as an investor.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.